LI 412
Alternative Names: BIO412; Dermatitis therapies - Enhance Biotech; Itch therapies - Enhance Biotech; LI 412 family; LIF 412; Urticaria therapies - Enhance BiotechLatest Information Update: 22 Feb 2007
At a glance
- Originator Enhance Lifesciences
- Class
- Mechanism of Action Histamine receptor antagonists; Serotonin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atopic dermatitis; Contact dermatitis; Urticaria
Most Recent Events
- 21 Apr 2004 Phase-II clinical trials in Atopic dermatitis in USA (Topical)
- 21 Apr 2004 Phase-II clinical trials in Contact dermatitis in USA (Topical)
- 21 Apr 2004 Phase-II clinical trials in Urticaria in USA (PO)